Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Incorporation of crizotinib into the NCCN guidelines.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Dec 2011

Riely Gregory J, Chaft Jamie E, Ladanyi Marc, Kris Mark G

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Crizotinib
Share to Medical Oncology
Share to Molecular Diagnostic Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Practice Guidelines as Topic

Share to Pyrazoles

Share to Pyridines

Share to Societies, Medical

Source

Identifiers

PMID: 22157552
DOI: 10.6004/jnccn.2011.0113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Incorporation of crizotinib into the NCCN guidelines.PMID 22157552Read ↗

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.Semantic proximity Read ↗

Resistance: Crizotinib makes a comeback.Semantic proximity Read ↗

Successful crizotinib retreatment after crizotinib-induced interstitial lung disease.Semantic proximity Read ↗

[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)].Semantic proximity Read ↗

[Individualized drug therapy].Semantic proximity Read ↗

[Pharmacological and clinical profiles of panitumumab injection (Vectibix®)].Semantic proximity Read ↗

Management of NSCLC: focus on crizotinib.Semantic proximity Read ↗

[HAART-update for the general practitioner].Semantic proximity Read ↗

Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.Semantic proximity Read ↗

Task Force on Strategic Research Direction: Clinical Science Subgroup key science topics report.Semantic proximity Read ↗

Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.Semantic proximity Read ↗

New drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.